Migration of human dendritic cells after injection in patients with metastatic malignancies - PubMed (original) (raw)
Affiliations
- PMID: 9892184
Migration of human dendritic cells after injection in patients with metastatic malignancies
M A Morse et al. Cancer Res. 1999.
Abstract
Present clinical studies of active immunotherapy for malignancies using dendritic cells (DCs) require elucidation of the sites where DCs localize after injection. We evaluated the pattern of distribution of in vitro-generated, antigen-loaded, human DCs labeled with indium-111 oxyquinoline after i.v., s.c., and intradermal injection. Whereas the DCs injected i.v. localized in the lungs and then redistributed to the liver, spleen, and bone marrow, they were not detected in lymph nodes or tumors. A small percentage of DCs injected intradermally migrated rapidly to the regional lymphatics in some individuals. No lymph node activity was detected after s.c. injection. Our results demonstrate that DC distribution to sites of lymphoid tissue is dramatically affected by the mode of administration.
Similar articles
- A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. Morse MA, et al. Clin Cancer Res. 1999 Jun;5(6):1331-8. Clin Cancer Res. 1999. PMID: 10389916 Clinical Trial. - Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Eggert AA, et al. Cancer Res. 1999 Jul 15;59(14):3340-5. Cancer Res. 1999. PMID: 10416590 - Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JF, Blokx W, Vankrieken JH, Joosten I, Boerman OC, Oyen WJ, Adema G, Punt CJ, Figdor CG, de Vries IJ. Verdijk P, et al. Clin Cancer Res. 2009 Apr 1;15(7):2531-40. doi: 10.1158/1078-0432.CCR-08-2729. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318472 - Migration of dendritic cell based cancer vaccines: in vivo veritas?
Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Adema GJ, et al. Curr Opin Immunol. 2005 Apr;17(2):170-4. doi: 10.1016/j.coi.2005.01.004. Curr Opin Immunol. 2005. PMID: 15766677 Review. - Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT. Shu S, et al. Cancer Metastasis Rev. 2006 Jun;25(2):233-42. doi: 10.1007/s10555-006-8503-7. Cancer Metastasis Rev. 2006. PMID: 16770535 Review.
Cited by
- mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.
Van Lint S, Heirman C, Thielemans K, Breckpot K. Van Lint S, et al. Hum Vaccin Immunother. 2013 Feb;9(2):265-74. doi: 10.4161/hv.22661. Epub 2013 Jan 4. Hum Vaccin Immunother. 2013. PMID: 23291946 Free PMC article. Review. - Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.
Guo S, Xu J, Denning W, Hel Z. Guo S, et al. Gene Ther. 2009 Nov;16(11):1300-13. doi: 10.1038/gt.2009.93. Epub 2009 Jul 30. Gene Ther. 2009. PMID: 19641529 Free PMC article. - Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.
Dillman RO, Nistor GI, Keirstead HS. Dillman RO, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2198467. doi: 10.1080/21645515.2023.2198467. Epub 2023 May 3. Hum Vaccin Immunother. 2023. PMID: 37133853 Free PMC article. - Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.
Matsuo K, Yoshie O, Kitahata K, Kamei M, Hara Y, Nakayama T. Matsuo K, et al. Cancers (Basel). 2021 May 20;13(10):2495. doi: 10.3390/cancers13102495. Cancers (Basel). 2021. PMID: 34065346 Free PMC article. Review. - Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.
Matsushita N, Komine H, Grolleau-Julius A, Pilon-Thomas S, Mulé JJ. Matsushita N, et al. Cancer Immunol Immunother. 2010 Jun;59(6):875-84. doi: 10.1007/s00262-009-0813-5. Epub 2010 Jan 8. Cancer Immunol Immunother. 2010. PMID: 20054688 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources